Junctucell

Junctucell is a Swiss biotechnology company focused on developing first-in-class small molecule therapeutics that target gap junction proteins, specifically Connexin 43 (Cx43). The company's approach centers on modulating the communication between tumor cells and the tumor microenvironment to overcome therapy resistance and inhibit metastasis. By targeting the 'junctome,' Junctucell aims to restore normal cellular signaling and enhance the efficacy of existing standard-of-care treatments, including chemotherapy and immunotherapy. Their lead programs are currently in the pre-clinical stage, with a primary focus on aggressive solid tumors such as glioblastoma and metastatic breast cancer.